Recently, a randomized, multicenter phase II study indicated that a association of atezolizumab (anti-PD-L1 inhibitor) and cobimetinib (MEK inhibitor) was effective in advanced CCA patients with prior first-line or second-line treatment. The gene discussed is CD274; the disease is cholangiocarcinoma.